QQQ   282.82 (-0.48%)
AAPL   116.33 (-0.46%)
MSFT   213.20 (-0.74%)
FB   277.83 (-0.32%)
GOOGL   1,594.03 (+0.51%)
AMZN   3,147.41 (-1.18%)
TSLA   428.04 (+1.28%)
NVDA   540.21 (-0.14%)
BABA   306.15 (-0.59%)
CGC   19.39 (-0.51%)
GE   7.48 (+2.19%)
MU   53.50 (+0.36%)
AMD   79.45 (+0.32%)
T   28.18 (+5.46%)
F   7.89 (+0.51%)
ACB   4.67 (-3.71%)
GILD   59.92 (-0.48%)
NFLX   485.59 (-0.71%)
BA   164.56 (+0.43%)
NIO   27.38 (-1.72%)
DIS   126.15 (-0.38%)
QQQ   282.82 (-0.48%)
AAPL   116.33 (-0.46%)
MSFT   213.20 (-0.74%)
FB   277.83 (-0.32%)
GOOGL   1,594.03 (+0.51%)
AMZN   3,147.41 (-1.18%)
TSLA   428.04 (+1.28%)
NVDA   540.21 (-0.14%)
BABA   306.15 (-0.59%)
CGC   19.39 (-0.51%)
GE   7.48 (+2.19%)
MU   53.50 (+0.36%)
AMD   79.45 (+0.32%)
T   28.18 (+5.46%)
F   7.89 (+0.51%)
ACB   4.67 (-3.71%)
GILD   59.92 (-0.48%)
NFLX   485.59 (-0.71%)
BA   164.56 (+0.43%)
NIO   27.38 (-1.72%)
DIS   126.15 (-0.38%)
QQQ   282.82 (-0.48%)
AAPL   116.33 (-0.46%)
MSFT   213.20 (-0.74%)
FB   277.83 (-0.32%)
GOOGL   1,594.03 (+0.51%)
AMZN   3,147.41 (-1.18%)
TSLA   428.04 (+1.28%)
NVDA   540.21 (-0.14%)
BABA   306.15 (-0.59%)
CGC   19.39 (-0.51%)
GE   7.48 (+2.19%)
MU   53.50 (+0.36%)
AMD   79.45 (+0.32%)
T   28.18 (+5.46%)
F   7.89 (+0.51%)
ACB   4.67 (-3.71%)
GILD   59.92 (-0.48%)
NFLX   485.59 (-0.71%)
BA   164.56 (+0.43%)
NIO   27.38 (-1.72%)
DIS   126.15 (-0.38%)
QQQ   282.82 (-0.48%)
AAPL   116.33 (-0.46%)
MSFT   213.20 (-0.74%)
FB   277.83 (-0.32%)
GOOGL   1,594.03 (+0.51%)
AMZN   3,147.41 (-1.18%)
TSLA   428.04 (+1.28%)
NVDA   540.21 (-0.14%)
BABA   306.15 (-0.59%)
CGC   19.39 (-0.51%)
GE   7.48 (+2.19%)
MU   53.50 (+0.36%)
AMD   79.45 (+0.32%)
T   28.18 (+5.46%)
F   7.89 (+0.51%)
ACB   4.67 (-3.71%)
GILD   59.92 (-0.48%)
NFLX   485.59 (-0.71%)
BA   164.56 (+0.43%)
NIO   27.38 (-1.72%)
DIS   126.15 (-0.38%)
Log in
NYSEAMERICAN:OCX

OncoCyte Stock Forecast, Price & News

$1.57
-0.02 (-1.26 %)
(As of 10/22/2020 10:25 AM ET)
Add
Compare
Today's Range
$1.57
Now: $1.57▼
$1.64
50-Day Range N/A
52-Week Range
$1.15
Now: $1.57▼
$3.51
Volume1,163 shs
Average Volume741,843 shs
Market Capitalization$105.58 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer. The company was founded in 2009 and is based in Alameda, California. OncoCyte Corporation is a subsidiary of BioTime, Inc.
Read More
OncoCyte logo

Beat the Market (BTM) Rank™

Analyst Opinion: 3.2Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.80 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:OCX
Previous SymbolAMEX:OCX
CUSIPN/A
CIK1642380
Webwww.oncocyte.com
Phone(510) 775-0515
Employees12

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding Shares67,251,000
Market Cap$105.58 million
Next Earnings Date11/12/2020 (Estimated)
OptionableNot Optionable
$1.57
-0.02 (-1.26 %)
(As of 10/22/2020 10:25 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive OCX News and Ratings via Email

Sign-up to receive the latest news and ratings for OCX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











OncoCyte (NYSEAMERICAN:OCX) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of OncoCyte?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for OncoCyte.

When is OncoCyte's next earnings date?

OncoCyte is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for OncoCyte.

How were OncoCyte's earnings last quarter?

OncoCyte Corp (NYSEAMERICAN:OCX) announced its earnings results on Wednesday, July, 29th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by $0.03. The biotechnology company earned $0.14 million during the quarter, compared to analysts' expectations of $0.04 million.
View OncoCyte's earnings history.

What price target have analysts set for OCX?

5 Wall Street analysts have issued twelve-month target prices for OncoCyte's shares. Their forecasts range from $2.00 to $7.50. On average, they anticipate OncoCyte's share price to reach $4.30 in the next year. This suggests a possible upside of 173.9% from the stock's current price.
View analysts' price targets for OncoCyte.

Are investors shorting OncoCyte?

OncoCyte saw a increase in short interest during the month of September. As of September 30th, there was short interest totaling 2,810,000 shares, an increase of 24.9% from the September 15th total of 2,250,000 shares. Based on an average trading volume of 840,600 shares, the days-to-cover ratio is currently 3.3 days.
View OncoCyte's Short Interest.

Who are some of OncoCyte's key competitors?

Some companies that are related to OncoCyte include Novacyt (NCYT), Ergomed (ERGO), Altimmune (ALT), Altimmune (ALT), Silence Therapeutics (SLN), Ibio (IBIO), ProMetic Life Sciences (PLI), IMV Inc. (IMV.TO) (IMV), Neptune Wellness Solutions Inc. (NEPT.TO) (NEPT), Rafael (RFL), Tiziana Life Sciences (TILS), Emblem (EMC), Medicenna Therapeutics (MDNA), Fennec Pharmaceuticals Inc. (FRX.TO) (FRX) and Resverlogix (RVX).
View all competitors.

What other stocks do shareholders of OncoCyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OncoCyte investors own include Alibaba Group (BABA), BioTime (BTX), Fulcrum Therapeutics (FULC), Alnylam Pharmaceuticals (ALNY), VIVUS (VVUS), Anavex Life Sciences (AVXL), CymaBay Therapeutics (CBAY), AcelRx Pharmaceuticals (ACRX), Agile Therapeutics (AGRX) and Aldeyra Therapeutics (ALDX).

Who are OncoCyte's key executives?

OncoCyte's management team includes the following people:
  • Mr. William Annett, Pres, CEO & Director (Age 65)
  • Mr. Mitchell S. Levine, Chief Financial Officer
  • Dr. Lyndal K. Hesterberg, Chief Scientific Officer
  • Mr. Albert P. Parker II, Chief Operating Officer
  • Dr. Michael D. West, Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc. (Age 66)

What is OncoCyte's stock symbol?

OncoCyte trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OCX."

How do I buy shares of OncoCyte?

Shares of OCX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is OncoCyte's stock price today?

One share of OCX stock can currently be purchased for approximately $1.57.

How big of a company is OncoCyte?

OncoCyte has a market capitalization of $105.58 million. OncoCyte employs 12 workers across the globe.

What is OncoCyte's official website?

The official website for OncoCyte is www.oncocyte.com.

How can I contact OncoCyte?

OncoCyte's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at (510) 775-0515.

This page was last updated on 10/22/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.